MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

CareDx Inc

Suletud

SektorTervishoid

19.17 -1.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.9

Max

19.48

Põhinäitajad

By Trading Economics

Sissetulek

10M

1.7M

Müük

13M

100M

P/E

Sektori keskmine

15.641

78.892

Kasumimarginaal

1.674

Töötajad

644

EBITDA

11M

6.8M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+12.94% upside

Turustatistika

By TradingEconomics

Turukapital

279M

1.1B

Eelmine avamishind

20.76

Eelmine sulgemishind

19.17

Uudiste sentiment

By Acuity

50%

50%

149 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

CareDx Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. dets 2025, 22:03 UTC

Suurimad hinnamuutused turgudel

Mining Stocks Slip Near the End of Stellar Year

29. dets 2025, 15:57 UTC

Suurimad hinnamuutused turgudel

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29. dets 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29. dets 2025, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Manus: Will Continue to Operate From Singapore

29. dets 2025, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29. dets 2025, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Will Integrate Manus Service Into Products

29. dets 2025, 23:36 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Will Continue to Operate, Sell Manus Service

29. dets 2025, 23:36 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29. dets 2025, 23:35 UTC

Omandamised, ülevõtmised, äriostud

Manus to Join Meta Platforms

29. dets 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Origin: Raise Values Kraken at US$8.65 Billion

29. dets 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Origin: Octopus Targeting Kraken Separation by Mid 2026

29. dets 2025, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29. dets 2025, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin's Kraken Stake to Remain at 22.7%

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin: Additional Interest Offsets Dilution From Raise

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29. dets 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29. dets 2025, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29. dets 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

CareDx Inc Prognoos

Hinnasiht

By TipRanks

12.94% tõus

12 kuu keskmine prognoos

Keskmine 22 USD  12.94%

Kõrge 26 USD

Madal 18 USD

Põhineb 4 Wall Streeti analüütiku instrumendi CareDx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

14.77 / 18.49Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

149 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat